Clinical trials: X Linked Hypohidrotic Ectodermal Dysplasia

X-Linked Hypohidrotic Ectodermal Dysplasia

Phase 2 Study to Evaluate Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200 in Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)

• Completed
• Age: 48 hours to 14 days
• Phase 2

This Phase 2 first-in-neonate EDI200 study will enroll treatment-naïve, XLHED-affected male newborns in the first two weeks of life.

Trial name

ECP-002 (NCT01775462)

Testing

EDI200

Where

7 sites in United States, France and 3 more

Volunteers

6 people

Sponsor

Edimer Pharmaceuticals